As gene therapy moves toward broader commercialization, the pressure to streamline production and ensure consistent, high-quality output has never been greater. Here, we explore strategies to develop simplified, scalable state-of-the-art platforms designed to optimize AAV yields and process efficiency. Whether you're facing bottlenecks in upstream development, struggling with analytical limitations, or exploring safer, more efficient alternatives to viral vectors, this session delivers practical insights grounded in real-world data and case studies.
This webinar will walk you through novel approaches to AAV production using stable producer cell lines achieving a titer higher than 1E12 vg/mL with > 30% full capsid at harvest. We explore innovative robust analytics for comprehensive product characterization looking at AAV genomic integrity and its correlation with orthogonal analytical methods. We will also introduce emerging non-viral delivery systems including extracellular vesicles (exosomes) which counter concerns around viral vector safety and toxicity. Here, we elaborate on vector and cell line development to build a platform-based approach to manufacturing.
Attendees will learn about: